Atopic dermatitis (AD) is a common, chronic inflammatory skin condition, and patients with moderate-to-severe disease often require systemic therapy. Since 2017, targeted systemic agents, biologics and Janus kinase (JAK) inhibitors, have expanded treatment options available, but comparative evidence remains limited...
Vasiliki Pikoula, E. Zafiriou, A. Bewley et al.· Frontiers in Immunology· 0 citations
BACKGROUND
Atopic dermatitis (AD) in the elderly is increasing worldwide and presents therapeutic challenges due to age-related comorbidities that often contraindicate systemic therapies. Although oral Janus kinase (JAK) inhibitors show efficacy in moderate-to-severe AD, older adult patients are underrepresented in cli...
E. Ippoliti, N. Gori, G. Coscarella et al.· Dermatitis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.